Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

40.0%

-46.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 4

2(33.3%)

6Total

N/A(4)

Phase 4(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07277296Not ApplicableNot Yet Recruiting

CGUARDIANS III IDE Pivotal Trial

Role: lead

NCT06653387Not ApplicableRecruiting

A Single-arm, Pivotal Study to Evaluate Acute Device and Technical Success of the CGuard Prime Carotid Stent System When Used in Conjunction to the ENROUTE Transcarotid Neuroprotection System in Patients Undergoing Carotid Artery Stenting Via the Transcarotid Artery Revascularization Approach

Role: lead

NCT04900844Not ApplicableActive Not Recruiting

Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting

Role: lead

NCT04234854Unknown

OPTIMAl Endovascular Exclusion of Consecutive Patient High-risk Carotid Plaque Using the MicroNet Covered Stent

Role: collaborator

NCT01869738Not ApplicableTerminated

MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction

Role: lead

NCT02292823Terminated

MGuard™ Prime Embolic Protection Stent in Patients With Acute ST Elevation Myocardial Infarction